Regeneron - long-term growth prospects According to Benchma | 🚀 Robin Rocket

Regeneron - long-term growth prospects

According to Benchmark analysts, Regeneron Pharmaceuticals has prospects not only during the pandemic, but also for a long time after its end.

Regeneron Pharmaceuticals $REGN is a biotechnology company that develops, manufactures and markets pharmaceuticals.
Target price from Benchmark - $727, upside potential +7%

Theses in favor of the company's growth:

• Phase 3 trials of Dupixent for the treatment of atopic dermatitis in children aged six months to five years have shown positive results. It was the first biological drug to show positive results in this group. Dupixent is also planned to be used to treat other autoimmune diseases.

Analysts believe that by the end of 2021, Dupixent sales will reach $5.6 billion, and by 2030 - $21 billion. This drug may become the most popular in the world.

• REGEN-COV vaccine. In the second quarter, the US government purchased about 1 million doses of the drug for the treatment of coronavirus in the amount of $2.6 billion. The drug is approved by the FDA and is used to treat some patients with Covid-19, as well as its prevention.

Fundamental indicators:

• Market Cap: $72.27 billion
• fwd P/E = 16x
• fwd P/E sectors = 19.4x
• PEG = 3x

Not an investment recommendation.